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ABSTRACT 
Background:  Colorectal cancer incidence was reduced among women assigned to 
active treatment in the Women’s Health Initiative (WHI) estrogen plus progestin 
randomized trial, but the interpretation was obscured by an associated later stage of 
diagnosis.  In contrast the estrogen-alone trial showed no incidence reduction or 
differential stage at diagnosis.  Here, data from the WHI observational study are 
considered, in conjunction with colorectal cancer mortality data from the hormone 
therapy trials, in an attempt to clarify postmenopausal hormone therapy effects.  
 
Participants and Methods:  Postmenopausal women aged 50-79 at WHI enrollment.  
Estrogen-alone analyses include 21,552 and 10,739 women who were post-
hysterectomy from the observational study and clinical trial respectively.  Estrogen plus 
progestin analyses include 32,084 and 16,608 observational study and clinical trial 
women with uterus.  Colorectal cancers were verified by central medical and pathology 
report review. 
 
Results:  Hazard ratios (95% confidence intervals) from the WHI observational study 
were 0.80 (0.53 to 1.20) for estrogen and 1.15 (0.74 to 1.79) for estrogen plus 
progestin, with respectively 168 and 175 women diagnosed with colorectal cancer.  
Delayed diagnosis with estrogen plus progestin is not evident in the observational study.  
No protective effect on colorectal cancer mortality in the estrogen plus progestin trial is 
seen over an 8-year intervention and follow-up period. 
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Conclusion:  Hazard ratio patterns in the WHI clinical trial and observational study do 
not provide strong evidence of a clinically important colorectal cancer benefit with either 
estrogen-alone or estrogen plus progestin over 7-8 years of treatment and follow-up. 
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INTRODUCTION 
Colorectal cancer was included in a ‘global index’ to summarize health benefits and 
risks in the WHI randomized controlled trials of daily 0.625 conjugated equine estrogens 
(CEE) versus placebo among 10,739 women who were post-hysterectomy, and this 
same estrogen preparation plus daily 2.5 mg of medroxyprogesterone acetate 
(CEE/MPA) among 16,608 postmenopausal women with a uterus (1, 2).  The CEE/MPA 
trial was stopped early in 2002 when it was judged that overall health risks exceeded 
benefits (3).  The (invasive) colorectal hazard ratio (HR) for the active treatment over a 
5.6-year average intervention period was 0.56 with a 95% confidence interval (CI) of 
0.38 to 0.81 (4).  However, the interpretation of this finding was substantially obscured 
by the fact that ‘colorectal cancers in women who took estrogen plus progestin were 
diagnosed at a more advanced stage than those in women who took placebo’ (4).  The 
CEE trial had health benefits and risks that were approximately balanced (5), but was 
also stopped early, in 2004, in part because of an elevation in stroke.  The colorectal 
cancer HR over the 7.1-year average follow-up period in the CEE trial was 1.12 with 
95% CI of 0.77 to 1.63, and there was no suggestion of an effect of CEE on diagnosis 
(6). 
 
Observational studies have mostly reported an inverse association with colorectal 
cancer incidence for either estrogen or estrogen plus progestin (7-9), though some 
studies (10-12) have reported lower colorectal cancer incidence among users of 
estrogen plus progestin, but not among estrogen-alone users. 
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The WHI observational study (OS) provides an opportunity to further explore the effects 
of these preparations on colorectal cancer, and to compare both incidence associations, 
and tumor characteristics between the WHI clinical trial (CT) and OS, for CEE and 
CEE/MPA.  The OS is a prospective cohort study among 93,676 postmenopausal 
women in the 50-79 year age range, who were drawn from the same populations as 
were CT women, with much commonality in protocol and procedures. 
 
WHI investigators have compared cardiovascular disease (13, 14) and breast cancer 
(15, 16) effects between the CT and OS, for both CEE and CEE/MPA.  Apparently 
discrepant findings for these outcomes could be explained mostly by taking suitable 
account of time from menopause to hormone therapy initiation, time since hormone 
therapy initiation, and applying standard confounding control procedures.  
Corresponding invasive colorectal cancer analyses are considered here.  Additional 
analyses examine hazard ratios for subsets of colorectal cancer defined by local versus 
regional/distant spread, primary tumor size, or the presence of positive lymph nodes.  
Colorectal cancer mortality data are also examined during the intervention period in the 
CEE trial, and during both the intervention period and post-intervention follow-up period 
in the CEE/MPA trial. 
 
MATERIALS AND METHODS 
Study Cohorts.  The design of the WHI clinical trial and observational study has been 
presented (17), and overall clinical trial findings have been recently summarized (18).  
All women were postmenopausal, in the age range 50-79, and without a medical 
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condition likely to result in death within three years, at the time of enrollment.  Women 
with a personal history of breast cancer were excluded from the hormone therapy trials.  
Characteristics of the OS cohort have been described (19). 
 
OS women were included in the CEE component of this analysis if they were post-
hysterectomy and either taking the same daily 0.625 mg CEE preparation as studied in 
the CT or not using any hormone therapy at the time of enrollment.  Women included 
were also required to have known values for a list of potential confounding factors.  
Women with a personal history of breast cancer at baseline, or without a mammogram 
in the two-year period prior to enrollment, were also excluded to correspond with CT 
exclusionary criteria, giving a subcohort of 21,552 OS women including 10,582 baseline 
CEE users, and 10,970 non-users.  A total of 32,084 OS women with uterus were 
included using these same criteria in the corresponding CEE/MPA component of this 
analysis, including 6756 women who were using the same daily CEE/MPA combination 
as studied in the CT, and 25,328 non-users.   
 
Information on lifetime hormone use was obtained at baseline from CT and OS women 
by trained interviewers, assisted by structured questionnaires and charts displaying 
colored photographs of various hormone preparations. 
 
Follow-up.  Clinical outcomes were reported semi-annually in the CT and annually in the 
OS (20).  Medical records documentation of initial self-reports were obtained and 
diagnoses were confirmed by physician adjudicators.  All colorectal cancer cases were 
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centrally reviewed and classified using SEER program guidelines (21).  Information on 
adherence to study hormone pills was obtained semi-annually in the CT, and 
information on hormone therapy use was updated annually by questionnaire in the OS. 
 
Statistical Analysis.  Statistical methods and variable definitions are similar to previous 
reports of this type (13-16), for other clinical outcomes.  Briefly, follow-up in the 
hormone therapy trials was included through the end of the respective intervention 
periods, while OS subcohorts were followed through December 15, 2004 for CEE 
analyses, and through February 28, 2003 for CEE/MPA analyses to give respective 
average follow-up periods of 7.1 and 5.5 years, similar to the CT.  Women in the HT 
trials were required to obtain mammograms annually, or study pills were withheld.  
Toward ensuring comparable exposure to the medical care system, follow-up times for 
women were censored at the first instance of being more than two years from most 
recent mammogram, in both the CT and OS. 
 
Hazard ratio estimation for colorectal cancer incidence was based on Cox regression 
(22), with time from WHI enrollment as the basic time variable.  The baseline hazard 
rate was stratified on age at enrollment in 5-year intervals and on a personal history of 
colorectal cancer at enrollment (yes vs. no) in both CT and OS analyses.  CT analyses 
also stratify on WHI dietary modification trial randomization (intervention, control, or not 
randomized).  OS analyses stratify also on prior postmenopausal hormone therapy (no 
versus hormone therapy prior to enrollment for non-users at baseline, or prior to the 
beginning of the ongoing hormone therapy episode for baseline hormone therapy users, 
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with a usage gap of one year or longer defining a new hormone therapy episode), and 
include baseline colorectal cancer risk factors, as listed below, in the hazard ratio 
regression model for confounding control (with separate regression coefficients for prior 
hormone therapy users and non-users).  Because of the random allocation, these 
factors were not included in the HR model in the CT, but randomization into the calcium 
and vitamin D clinical trial component (active, versus placebo or not randomized) was 
included as a time-dependent regression variable. 
 
Hazard ratios among adherent women were estimated using these same modeling 
procedures, with follow-up times censored six months after a change from baseline in 
hormone therapy status. For a non-user, a status change involved the initiation of any 
hormone therapy. For a baseline user a status change involved either  HT 
discontinuation, or a change to another HT preparation. 
 
Colorectal cancer mortality data and all-cause mortality data were also considered 
through the end of the active intervention periods for both clinical trials and for the 
CEE/MPA trial also through the end of a subsequent CT follow-up period ending 
3/31/05.  These analyses also used Cox models, with baseline hazard ratios stratified 
as in previous trial reports (3-6). 
 
Nominal 95% CIs are presented for hazard ratios, and all significance levels (p-values) 
are two-sided. 
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RESULTS 
Table 1 shows age-adjusted colorectal cancer incidence rates in the CT and OS 
cohorts, according to hormone therapy group, and prior use of hormone therapy for both 
CEE and CEE/MPA.  Age-adjusted incidence rates do not vary strongly among the non-
user groups according to uterine status, or prior hormone therapy use, but tend to be 
somewhat lower in the OS than in the CT. 
 
Table 2 shows invasive colorectal cancer hazard ratio estimates for CEE and CEE/MPA 
both from the CT as previously reported, and from the OS.  The HR (95% CI) for CEE 
from the OS is 0.80 (0.53, 1.20) with 168 colorectal cancer cases, while that for 
CEE/MPA from the OS is 1.15 (0.74, 1.79) with 175 cases.  Hence, OS data provide 
little evidence overall for a colorectal cancer association with either CEE or CEE/MPA.  
Potential confounding factors in OS analyses are listed in a Table 2 footnote. 
 
Additional joint analyses of the CT and OS data were carried out to provide more 
detailed HR comparisons.  Most hormone therapy users in the OS were some years into 
their ongoing hormone therapy episode at WHI enrollment, and the OS mostly 
contributes HR information well after therapy initiation.  Hence, separate HRs were 
calculated for 0-2, 2-5, and ≥5 years from hormone therapy initiation.  Table 3 shows 
results of these analyses, which also included product term between hormone therapy 
and cohort (CT vs. OS) to quantitatively judge overall HR agreement between the two 
sources.  Under this statistical model the hormone therapy HRs in the OS are restricted 
to differ from those in the CT by a simple multiplicative factor, for which an estimate and 
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95% confidence interval are shown in the final row of the left side of Table 3.  This ratio 
of HR in the OS to HR in the CT would be close to unity if HRs from the two sources 
agree, but note that CEE/MPA HRs in the OS are estimated to be 81% higher than in 
the CT, while CEE HRs in the OS are estimated to be 37% lower than in the CT, though 
neither ratio is significantly different from one.  The right side of Table 3 shows 
corresponding analyses among women who were adherent to their baseline hormone 
therapy group designation, by censoring the follow-up time six months following a 
change from baseline hormone therapy status.  Among adherent women, HRs do not 
agree closely between the CT and OS for either hormone therapy preparation. 
 
Additional analyses extended the Table 3 analyses by including an interaction term 
between hormone therapy and baseline age in the log-hazard ratio.  For CEE, a modest 
increase in HR with age could be detected (p=0.02) with the CEE HR increased by a 
factor of 1.19 (95% CI of 1.03 to 1.37) for each 5-year increment in age.  This 
interaction was also significant (p=0.02) among adherent women, with the CEE HR 
increased by 1.23 (95% CI of 1.03 to 1.47) for each 5-year age increment.  The 
corresponding hormone therapy by age interaction was not significant for CEE/MPA, but 
in the same direction with HR of 1.09 (95% CI of 0.84 to 1.42) without adherence 
restriction and with HR of 1.15 (95% CI of 0.85 to 1.55) among adherent women, for a 
5-year age increment.  We also examined the possibility of an interaction of hormone 
therapy HRs with time from menopause to first use of hormone therapy, but found little 
evidence of such dependency for CEE (p=0.15), or CEE/MPA (p=0.87) without 
adherence restriction, or for CEE (p=0.29) or CEE/MPA (p=0.54) among adherent 
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women.  Additional analyses of this type with focus on women who initiate CEE or 
CEE/MPA soon after the menopause can be found in (23) for a range of clinical 
outcomes, including colorectal cancer. 
 
To better understand suggested HR differences between the CT and OS, and hormone 
therapy effects more generally, the analyses of Table 2 were extended by calculating 
HRs separately according to metastatic spread, primary tumor size, and the presence of 
one or more positive lymph nodes.  Hazard ratio estimates and 95% CIs for related 
tumor subtypes are shown in Figure 1 for each preparation, separately for the CT and 
OS.  The previously-noted (4) deficit of early stage tumors with CEE/MPA in the CT is 
not evident in the OS.  In contrast, there appears to be some deficit of more advanced 
tumors with CEE in the OS that, as previously noted (6), is not evident in the CT. 
 
Colorectal cancer mortality data were considered to examine whether the lower 
incidence in the CT for women assigned to CEE/MPA translated to reduced colorectal 
cancer mortality.  Through the end of the active intervention period (July 7, 2002) there 
were 10 colorectal cancer deaths in each of the CEE/MPA and placebo groups, giving a 
colorectal cancer mortality HR (95% CI) of 0.95 (0.40 to 2.28) and logrank p-value of 
0.91.  Participating women were followed systematically through March 31, 2005 (24) by 
which time there were 18 colorectal cancer deaths in the CEE/MPA group and 17 in the 
placebo group, with HR (95% CI) of 1.00 (0.51 to 1.94) with logrank p=1.00.  Among the 
115 women diagnosed with colorectal cancer during the intervention phase of the 
CEE/MPA trial, 12 had died in the CEE/MPA group and 11 in the placebo group by the 
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end of the intervention period, giving a total mortality HR (95% CI) for CEE/MPA of 1.64 
(0.70 to 3.83) with p=0.25.  Among the 182 women diagnosed with colorectal cancer 
through March 31, 2005, there were 23 deaths in the CEE/MPA group and 21 in the 
placebo group, giving a total mortality HR (95% CI) of 1.54 (0.82 to 2.87) and p=0.18.  
 
Corresponding colorectal cancer mortality data from the CEE trial were also considered.  
Through the end of the intervention period (2/29/2004) there were 16 colorectal cancer 
deaths in the active arm and 17 in the placebo, with corresponding HR (95% CI) of 0.99 
(0.50 to 1.96) and logrank p-value of 0.99.  Among 111 women diagnosed with 
colorectal cancer, there were 16 deaths in each of the intervention groups, with all-
cause mortality HR (95% CI) of 0.75 (0.34 to 1.70) and logrank p-value of 0.49.  
 
DISCUSSION 
The data analyses presented here were undertaken to further the interpretation of a 
reduced colorectal cancer incidence with CEE/MPA, and lack of evidence of any CEE 
effect on colorectal cancer incidence in the WHI clinical trial.  The CEE/MPA finding was 
obscured (4) by a later stage diagnosis in the active treatment versus the placebo 
group, allowing the possibility that the treatment itself, or some aspect of the trial 
protocol, led to a delayed colorectal cancer diagnosis in the CEE/MPA group.  This 
concern is heightened by the WHI Observational Study findings herein presented, that 
provide no suggestion of a lower risk among women using the same CEE/MPA 
preparation as studied in the clinical trial compared to non-users of postmenopausal 
hormones, and little suggestion of a different extent of disease at diagnosis between 
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CEE/MPA users and non-users.  Furthermore, the reduced incidence in the active 
treatment group in the CEE/MPA trial is shown here to have not led to any suggestion of 
colorectal cancer mortality benefit during an average 8-year intervention and follow-up 
period.  It is important to note, however, that an even longer time period may be 
required to observe a mortality benefit from an actual reduction in the incidence of 
small, localized colorectal cancers. 
 
It is interesting to speculate on reasons for later stage diagnoses with CEE/MPA in the 
CT, but not in the OS.  One possible difference is that colorectal tumors among 
CEE/MPA users in the OS tended to be diagnosed many years following treatment 
initiation, compared to mostly within the first few years of use in the CT.  Hence, a 
limited-time response of colorectal tissue to CEE/MPA initiation having potential to 
impede the detection of small tumors, could affect CT and OS findings differentially.  
However, we see little evidence of time trends in HRs in either the CT or OS, though 
numbers of colorectal cancer events is small for this type of analysis (data not shown).  
Another possibility relates to vaginal bleeding:  Women assigned to CEE/MPA in the 
WHI trial experienced persistent vaginal bleeding to a greater extent than expected, and 
followed a protocol designed to manage bleeding while allowing them to continue with 
study hormones to the extent practical.  We reanalyzed the CEE/MPA trial data while 
including an interaction term between randomization assignment and vaginal bleeding 
as a time-dependent variable.  The colorectal cancer HR for CEE/MPA among women 
with bleeding was 0.54 with a 95% CI of 0.27 to 1.10, while that for women without 
bleeding was 0.57 with 95% CI of 0.38 to 0.86, so that this trial feature does not help to 
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explain any diagnostic delay in the CEE/MPA trial.  Hence, in summary, collective WHI 
data suggest that either the observed lower incidence was due to a comparatively 
delayed colorectal cancer detection in the CEE/MPA group perhaps as a result of 
attributing symptoms to hormone therapy use, in spite of intervention blinding, resulting 
in delayed evaluation; or simply as a chance occurrence.  Alternatively, CEE/MPA 
results could reflect an actual reduction in localized, small tumors that apparently do not 
imply a colorectal cancer mortality benefit over an average 8-year intervention and 
follow-up period. 
 
The CEE clinical trial did not suggest an effect on colorectal cancer incidence or on 
diagnosis (6).  The OS also does not suggest an effect of CEE on incidence overall, 
though there is some evidence for a deficit of larger, more advanced tumors at 
diagnosis among women using CEE.  This is the direction of bias that would be 
expected if hormone therapy users in the community are under greater health 
surveillance than non-users.  Efforts to control such bias, here through imposing 
mammography utilization requirements prior to and after WHI enrollment, may not be 
sufficient for complete avoidance of bias from this source.  The CEE trial does not 
provide evidence of any effect on colorectal cancer mortality over its 7.1-year average 
follow-up period.  Hence, our summary interpretation is that collective WHI data provide 
little evidence for an effect of CEE on colorectal cancer incidence. 
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In summary, hazard ratio patterns in the WHI clinical trial and observational study do not 
provide strong evidence of a clinically important colorectal cancer benefit with CEE or 
CEE/MPA over an average 7 to 8 year treatment and follow-up period. 
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Table 1.  Age-adjusted incidence rates of, and numbers of women developing, invasive colorectal cancer in the WHI 
hormone trials and in corresponding observational study subcohorts, according to prior use of postmenopausal hormone 
therapy (HT) and hysterectomy status. 
                                      
   
   
           
           
Without Uterus at Enrollment     
Clinical Trial 
 
  Observational Study 
   
  Prior HT*  No Yes No Yes 
         Placebo  CEE†   Placebo  CEE   Non‐User  CEE   Non‐User  CEE 
                        
Number of women             
               
               
               
 
   
   
                 
           
           
2770  2769   2659  2541 6541  8677 4429  1905 
Average age (yrs) 63.8  63.6 63.4  63.6 65.1  63.4 65.7  64.2 
Incidence rate† 1.52  1.65 1.21  1.47 1.31  0.73 0.86  1.66 
Number of cases
 
30  32 23  26 65  46 33  24 
     
With Uterus at Enrollment     
Clinical Trial 
   
  Observational Study 
   
  Prior HT*  No Yes No Yes 
Placebo  CEE/MPA†   Placebo  CEE/MPA Non‐User  CEE/MPA Non‐User  CEE/MPA 
                         
Number of women               
               
               
               
6020  6277 2082  2229 19668  5710 5660  1046 
Average age (yrs) 63.4  63.4 63.0  62.6 64.7  61.0 64.8  64.3 
Incidence rate‡ 1.64  1.00 1.53  0.70 0.97  1.08 1.06  0.72 
Number of cases 55  35 17  8 109  27 35  4 
                                      
                                                                              
* Prior HT is defined relative to WHI enrollment in the clinical trial and non-user group in the OS, and defined relative to the beginning of the on-
going hormone therapy episode at enrollment in the OS user groups. 
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†CEE, conjugated equine estrogens; CEE/MPA, conjugated equine estrogens plus medroxyprogesterone acetate. 
‡ Incidence rate per 1000 person years, adjusted to the 5-year age distribution in the respective clinical trials.
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Table 2.  Numbers of women diagnosed with colorectal cancer, hazard ratio (HR) estimates and 95% confidence intervals 
(CIs) from the WHI postmenopausal hormone therapy trial and observational study for conjugated equine estrogen (CEE) 
and for CEE plus medroxyprogesterone acetate (MPA). 
 
  CEE  Non‐User  HR*  95% CI CEE/MPA  Non‐User  HR*  95% CI 
Clinical Trial  58  53  1.12  0.77 ‐ 1.63   
   
43  72  0.56  0.38 ‐ 0.81 
Observational Study  70  98  0.80  0.53 ‐ 1.20 31  144  1.15  0.74 ‐ 1.79 
 
 
* HRs in the clinical trial are from a Cox regression stratified by age group at enrollment, dietary modification trial randomization, and prior 
colorectal cancer, with assignment to the calcium and vitamin D trial as a time-dependent covariate.  HRs in the observational study from a Cox 
regression model stratified by age group at enrollment, prior colorectal cancer, and prior postmenopausal hormone therapy, and adjusted for age 
(linear), body mass index, education, cigarette smoking, alcohol consumption, bilateral oophorectomy, type and duration of prior hormone therapy, 
family history of colorectal cancer, waist circumference, height, history of polyp removal, dietary selenium intake, non-steroidal anti-inflammatory 
drug use, and prior oral contraceptive use.  HR regression coefficients were estimated separately for prior postmenopausal therapy users and 
non-users. 
* From Cox regression analyses with stratification and adjustment variables as in Table 2 footnotes, based on combined clinical trial and 
observational study analyses that include an interaction between hormone therapy HR and cohort (CT vs. OS) that produces the ratio of hormone 
therapy HR in the OS to that in the CT shown at the bottom of the Table. 
HR* 95% CI HR* 95% CI HR* 95% CI HR* 95% CI
< 2 1.03 0.43 ‐ 2.47 0.90 0.44 ‐ 1.83 1.10 0.45 ‐ 2.67 0.89 0.39 ‐ 2.04
2 ‐ 5 1.20 0.47 ‐ 3.06 0.62 0.35 ‐ 1.09 1.45 0.42 ‐ 5.06 0.73 0.35 ‐ 1.54
> 5 0.98 0.47 ‐ 2.03 0.62 0.27 ‐ 1.46 1.83 0.51 ‐ 6.50 0.65 0.22 ‐ 1.88
< 2 0.78 0.27 ‐ 2.21   0.54 0.13 ‐ 2.19   0.91 0.31 ‐ 2.68   0.60 0.15 ‐ 2.47
2 ‐ 5 0.81 0.35 ‐ 1.90 0.32 0.09 ‐ 1.15 0.42 0.11 ‐ 1.57 0.31 0.07 ‐ 1.46
> 5 2.46 1.12 ‐ 5.38 0.60 0.19 ‐ 1.86 3.98 1.06 ‐ 4.86 0.84 0.20 ‐ 3.55
Ratio of HR in OS
to HR in CT 0.63 0.30 ‐ 1.34 1.81 0.82 ‐ 4.00 0.35 0.10 ‐ 1.23 1.62 0.61 ‐ 4.33
No prior hormone therapy
Prior hormone therapy
Years from
Hormone Therapy
Initiation
Without non‐adherence censoring With non‐adherence censoring
CEE CEE/MPA CEE CEE/MPA
 
Table 3.  Colorectal cancer hazard ratio estimates for CEE and CEE/MPA from combined analysis of WHI hormone 
therapy trial and observational study data. 
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FIGURE LEGEND 
Figure 1.  Colorectal cancer hazard ratios and 95% confidence intervals from WHI clinical 
trial and observational study for conjugated equine estrogen (CEE) and for CEE plus 
medroxyprogesterone acetate (MPA), according to three aspects of extent of disease at 
diagnosis. 
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